Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sparsentan

FDA-approved product (tablet, oral), marketed as Filspari.

Registered studies
11
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sparsentan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • IGA glomerulonephritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other agents acting on the renin-angiotensin system
FDA pharmacologic class
Angiotensin 2 Receptor Blocker; Endothelin Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli49.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

11registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sparsentan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sparsentan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

    NCT07224776 · start 2026-07-10

    Registered record
    Registry ID
    NCT07224776
    Conditions
    Proteinuric Renal Disease; Proteinuric Kidney Disease; Proteinuria; Proteinuria in Nephrotic Range
    Interventions
    sparsentan; No sparsentan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-07-10
    Completion
    2028-12-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProteinuric Renal Disease; Proteinuric Kidney Disease; Proteinuria; Proteinuria in Nephrotic Range
    Interventionsparsentan; No sparsentan
    PhasePhase 1
    Registry statusRecruiting

  • Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

    NCT07555301 · start 2026-06-01

    Registered record
    Registry ID
    NCT07555301
    Conditions
    IgA Nephropathy (IgAN)
    Interventions
    sparsentan; sparsentan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-06-01
    Completion
    2029-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIgA Nephropathy (IgAN)
    Interventionsparsentan; sparsentan
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

    NCT07219121 · start 2025-10-07

    Registered record
    Registry ID
    NCT07219121
    Conditions
    Proteinuria; Immunoglobulin A (IgA) Nephropathy; Focal Segmental Glomerulosclerosis; Kidney Transplant
    Interventions
    Sparsentan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2025-10-07
    Completion
    2027-05
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProteinuria; Immunoglobulin A (IgA) Nephropathy; Focal Segmental Glomerulosclerosis; Kidney Transplant
    InterventionSparsentan
    PhasePhase 4
    Registry statusActive not recruiting

  • A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

    NCT05856760 · start 2023-05-19

    Registered record
    Registry ID
    NCT05856760
    Conditions
    Immunoglobulin A Nephropathy
    Interventions
    Sparsentan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-05-19
    Completion
    2024-10-25
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmunoglobulin A Nephropathy
    InterventionSparsentan
    PhasePhase 2
    Registry statusCompleted

  • ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)

    NCT05630612 · start 2022-12-08

    Registered record
    Registry ID
    NCT05630612
    Conditions
    ANCA Associated Vasculitis; Cardiovascular Diseases; Kidney Diseases
    Interventions
    Sparsentan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-12-08
    Completion
    2027-09-01
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionANCA Associated Vasculitis; Cardiovascular Diseases; Kidney Diseases
    InterventionSparsentan
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

    NCT05003986 · start 2021-08-12

    Registered record
    Registry ID
    NCT05003986
    Conditions
    Focal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy; IgA Vasculitis; Alport Syndrome
    Interventions
    Sparsentan; Sparsentan; Sparsentan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-08-12
    Completion
    2027-04-12
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFocal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy; IgA Vasculitis +1 more
    InterventionSparsentan; Sparsentan; Sparsentan
    PhasePhase 2
    Registry statusRecruiting

  • A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

    NCT04663204 · start 2020-12-10

    Registered record
    Registry ID
    NCT04663204
    Conditions
    Immunoglobulin A Nephropathy; Kidney Diseases; Glomerulonephritis, IGA; Glomerulonephritis; Autoimmune Diseases; Immune System Diseases
    Interventions
    Sparsentan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2020-12-10
    Completion
    2027-12-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmunoglobulin A Nephropathy; Kidney Diseases; Glomerulonephritis, IGA; Glomerulonephritis +2 more
    InterventionSparsentan
    PhasePhase 2
    Registry statusRecruiting

  • Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension

    NCT05562362 · start 2020-06-18

    Registered record
    Registry ID
    NCT05562362
    Conditions
    Healthy Subjects
    Interventions
    RE-021, sparsentan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-06-18
    Completion
    2020-11-12
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionRE-021, sparsentan
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

    NCT03762850 · start 2018-12-11

    Registered record
    Registry ID
    NCT03762850
    Conditions
    Immunoglobulin A Nephropathy
    Interventions
    sparsentan; irbesartan; Dapagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2018-12-11
    Completion
    2026-07
    Enrolment
    406

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmunoglobulin A Nephropathy
    Interventionsparsentan; irbesartan; Dapagliflozin
    PhasePhase 3
    Registry statusActive not recruiting

  • Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

    NCT03493685 · start 2018-04-17

    Registered record
    Registry ID
    NCT03493685
    Conditions
    Focal Segmental Glomerulosclerosis
    Interventions
    sparsentan; Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-04-17
    Completion
    2026-03-19
    Enrolment
    371

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFocal Segmental Glomerulosclerosis
    Interventionsparsentan; Irbesartan
    PhasePhase 3
    Registry statusCompleted

  • Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

    NCT01613118 · start 2014-03

    Registered record
    Registry ID
    NCT01613118
    Conditions
    Focal Segmental Glomerulosclerosis
    Interventions
    RE-021 (Sparsentan); Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03
    Completion
    2024-03-25
    Enrolment
    109

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFocal Segmental Glomerulosclerosis
    InterventionRE-021 (Sparsentan); Irbesartan
    PhasePhase 2
    Registry statusCompleted